Mintz Levin Represents Intercept Pharmaceuticals Inc. in Follow-On Public Offering Business Wire BOSTON -- July 1, 2013 Attorneys in the Life Sciences Practice of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. represented Intercept Pharmaceuticals, Inc. in the completion of its previously announced underwritten public offering of 1,730,000 shares of its common stock at a public offering price of $33.01 per share. In addition, the underwriters have exercised in full their option to purchase an additional 259,500 shares of common stock at the public offering price. Intercept Pharmaceuticals is a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases. All of the shares in the offering were sold by Intercept, with net proceeds to Intercept of approximately $61.7 million, after deducting underwriting discounts and commissions and estimated offering expenses. BofA Merrill Lynch and Citigroup acted as joint book-running managers, BMO Capital Markets acted as lead manager and Needham & Company, Wedbush PacGrow Life Sciences and Janney Montgomery Scott acted as co-managers for the offering. Representing Intercept in the offering were Bill Whelan, a Member of Mintz Levin’s Corporate & Securities Section and Co-Chair of the Life Sciences Practice Group, Scott Samuels, a Member of the Corporate & Securities Section and Life Sciences Practice, and Tavis Morello and Caroline Gammill, attorneys in the firm’s Corporate & Securities Section. Mintz Levin has served as one of the leading law firms to the life sciences industry since the industry’s birth in the 1970s. Today, the firm advises hundreds of businesses and other organizations in all sectors of the industry’s ecosystem -- from start-ups looking for their first funding to public companies with products on the market, as well as venture capital firms, investment banks, and research and academic institutions. Mintz Levin attorneys provide experienced counsel to clients globally in a broad range of matters, including corporate finance and securities, mergers and acquisitions, licensing and collaborations, intellectual property, litigation, regulatory, employment and benefits, bankruptcy and commercial lending, immigration, and real estate. Mintz Levin is a full-service law firm comprised of 450 attorneys with eight offices (Boston, New York, San Diego, San Francisco, Washington, Stamford, Los Angeles, and London) and an affiliate relationship in Israel. For more information about Mintz Levin, please visit www.mintz.com Contact: Mintz Levin Meg O’Donnell, 617-348-4956 MSODONNELL@MINTZ.COM
Mintz Levin Represents Intercept Pharmaceuticals Inc. in Follow-On Public Offering
Press spacebar to pause and continue. Press esc to stop.